|
1
|
Mao C and Obeid LM: Ceramidases:
Regulators of cellular responses mediated by ceramide, sphingosine,
and sphingosine-1-phosphate. Biochim Biophys Acta. 1781:424–434.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vethakanraj HS, Babu TA, Sudarsanan GB,
Duraisamy PK and Kumar Ashok S: Targeting ceramide metabolic
pathway induces apoptosis in human breast cancer cell lines.
Biochem Biophys Res Commun. 464:833–839. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu X, Elojeimy S, Turner LS, Mahdy AE,
Zeidan YH, Bielawska A, Bielawski J, Dong JY, El-Zawahry AM, Guo
GW, et al: Acid ceramidase inhibition: a novel target for cancer
therapy. Front Biosci. 13:2293–2298. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Seelan RS, Qian C, Yokomizo A, Bostwick
DG, Smith DI and Liu W: Human acid ceramidase is overexpressed but
not mutated in prostate cancer. Genes Chromosomes Cancer.
29:137–146. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Roh JL, Park JY, Kim EH and Jang HJ:
Targeting acid ceramidase sensitises head and neck cancer to
cisplatin. Eur J Cancer. 52:163–172. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Realini N, Palese F, Pizzirani D, Pontis
S, Basit A, Bach A, Ganesan A and Piomelli D: Acid ceramidase in
melanoma: Expression, localization and effects of pharmacological
inhibition. J Biol Chem. 291:2422–2434. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Morales A, París R, Villanueva A, Llacuna
L, García-Ruiz C and Fernández-Checa JC: Pharmacological inhibition
or small interfering RNA targeting acid ceramidase sensitizes
hepatoma cells to chemotherapy and reduces tumor growth in vivo.
Oncogene. 26:905–916. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Morad SA, Messner MC, Levin JC,
Abdelmageed N, Park H, Merrill AH Jr and Cabot MC: Potential role
of acid ceramidase in conversion of cytostatic to cytotoxic
end-point in pancreatic cancer cells. Cancer Chemother Pharmacol.
71:635–645. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: European Organisation for Research and Treatment of
Cancer Brain Tumor and Radiotherapy Groups; National Cancer
Institute of Canada Clinical Trials Group: Radiotherapy plus
concomitant and adjuvant temozolomide for glioblastoma. N Engl J
Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Iwamoto FM, Abrey LE, Beal K, Gutin PH,
Rosenblum MK, Reuter VE, DeAngelis LM and Lassman AB: Patterns of
relapse and prognosis after bevacizumab failure in recurrent
glioblastoma. Neurology. 73:1200–1206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wong ET, Hess KR, Gleason MJ, Jaeckle KA,
Kyritsis AP, Prados MD, Levin VA and Yung WK: Outcomes and
prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol. 17:2572–2578. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lamborn KR, Yung WK, Chang SM, Wen PY,
Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink
KL, et al: North American Brain Tumor Consortium: Progression-free
survival: An important end point in evaluating therapy for
recurrent high-grade gliomas. Neuro Oncol. 10:162–170. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q,
Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem
cells promote radioresistance by preferential activation of the DNA
damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mahdy AE, Cheng JC, Li J, Elojeimy S,
Meacham WD, Turner LS, Bai A, Gault CR, McPherson AS, Garcia N, et
al: Acid ceramidase upregulation in prostate cancer cells confers
resistance to radiation: AC inhibition, a potential
radiosensitizer. Mol Ther. 17:430–438. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cheng JC, Bai A, Beckham TH, Marrison ST,
Yount CL, Young K, Lu P, Bartlett AM, Wu BX, Keane BJ, et al:
Radiation-induced acid ceramidase confers prostate cancer
resistance and tumor relapse. J Clin Invest. 123:4344–4358. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Visentin B, Vekich JA, Sibbald BJ, Cavalli
AL, Moreno KM, Matteo RG, Garland WA, Lu Y, Yu S, Hall HS, et al:
Validation of an anti-sphingosine-1-phosphate antibody as a
potential therapeutic in reducing growth, invasion, and
angiogenesis in multiple tumor lineages. Cancer Cell. 9:225–238.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
O'Brien N, Jones ST, Williams DG,
Cunningham HB, Moreno K, Visentin B, Gentile A, Vekich J,
Shestowsky W, Hiraiwa M, et al: Production and characterization of
monoclonal anti-sphingosine-1-phosphate antibodies. J Lipid Res.
50:2245–2257. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Allred DC, Harvey JM, Berardo M and Clark
GM: Prognostic and predictive factors in breast cancer by
immunohistochemical analysis. Mod Pathol. 11:155–168.
1998.PubMed/NCBI
|
|
19
|
Bielawski J, Szulc ZM, Hannun YA and
Bielawska A: Simultaneous quantitative analysis of bioactive
sphingolipids by high-performance liquid chromatography-tandem mass
spectrometry. Methods. 39:82–91. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Visentin B, Reynolds G and Sabbadini R:
Immunohistochemical detection of sphingosine-1-phosphate and
sphingosine kinase-1 in human tissue samples. Methods Mol Biol.
874:55–67. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ogretmen B and Hannun YA: Biologically
active sphingolipids in cancer pathogenesis and treatment. Nat Rev
Cancer. 4:604–616. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Realini N, Solorzano C, Pagliuca C,
Pizzirani D, Armirotti A, Luciani R, Costi MP, Bandiera T and
Piomelli D: Discovery of highly potent acid ceramidase inhibitors
with in vitro tumor chemosensitizing activity. Sci Rep. 3:10352013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lacroix M, Abi-Said D, Fourney DR,
Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch
SJ, Holland E, et al: A multivariate analysis of 416 patients with
glioblastoma multiforme: Prognosis, extent of resection, and
survival. J Neurosurg. 95:190–198. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ballman KV, Buckner JC, Brown PD, Giannini
C, Flynn PJ, LaPlant BR and Jaeckle KA: The relationship between
six-month progression-free survival and 12-month overall survival
end points for phase II trials in patients with glioblastoma
multiforme. Neuro-oncol. 9:29–38. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hou LC, Veeravagu A, Hsu AR and Tse VC:
Recurrent glioblastoma multiforme: A review of natural history and
management options. Neurosurg Focus. 20:E52006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hannun YA and Obeid LM: Principles of
bioactive lipid signalling: Lessons from sphingolipids. Nat Rev Mol
Cell Biol. 9:139–150. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Park JH and Schuchman EH: Acid ceramidase
and human disease. Biochim Biophys Acta. 1758:2133–2138. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ségui B, Andrieu-Abadie N, Jaffrézou JP,
Benoist H and Levade T: Sphingolipids as modulators of cancer cell
death: Potential therapeutic targets. Biochim Biophys Acta.
1758:2104–2120. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Young N and Van Brocklyn JR: Roles of
sphingosine-1-phosphate (S1P) receptors in malignant behavior of
glioma cells. Differential effects of S1P2 on cell migration and
invasiveness. Exp Cell Res. 313:1615–1627. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Johnson IR, Parkinson-Lawrence EJ, Butler
LM and Brooks DA: Prostate cell lines as models for biomarker
discovery: Performance of current markers and the search for new
biomarkers. Prostate. 74:547–560. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Young N, Pearl DK and Van Brocklyn JR:
Sphingosine-1-phosphate regulates glioblastoma cell invasiveness
through the urokinase plasminogen activator system and CCN1/Cyr61.
Mol Cancer Res. 7:23–32. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pettus BJ, Chalfant CE and Hannun YA:
Ceramide in apoptosis: An overview and current perspectives.
Biochim Biophys Acta. 1585:114–125. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zeidan YH, Jenkins RW, Korman JB, Liu X,
Obeid LM, Norris JS and Hannun YA: Molecular targeting of acid
ceramidase: Implications to cancer therapy. Curr Drug Targets.
9:653–661. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu Y, He J, Xie X, Su G, Teitz-Tennenbaum
S, Sabel MS and Lubman DM: Serum autoantibody profiling using a
natural glycoprotein microarray for the prognosis of early
melanoma. J Proteome Res. 9:6044–6051. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang L, Wang X, Bullock AJ, Callea M,
Shah H, Song J, Moreno K, Visentin B, Deutschman D, Alsop DC, et
al: Anti-S1P antibody as a novel therapeutic strategy for VEGFR
TKI-resistant renal cancer. Clin Cancer Res. 21:1925–1934. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Abuhusain HJ, Matin A, Qiao Q, Shen H,
Kain N, Day BW, Stringer BW, Daniels B, Laaksonen MA, Teo C, et al:
A metabolic shift favoring sphingosine 1-phosphate at the expense
of ceramide controls glioblastoma angiogenesis. J Biol Chem.
288:37355–37364. 2013. View Article : Google Scholar : PubMed/NCBI
|
